Matches in SemOpenAlex for { <https://semopenalex.org/work/W1963500532> ?p ?o ?g. }
- W1963500532 endingPage "170" @default.
- W1963500532 startingPage "165" @default.
- W1963500532 abstract "Bezafibrate and fenofibrate show different binding properties against peroxisome proliferator-activated receptor subtypes, which could cause different clinical effects on circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) levels and on various metabolic markers.An open, randomized, four-phased crossover study using 400 mg of bezafibrate or 200mg of fenofibrate was performed. Study subjects were 14 dyslipidemia with impaired glucose tolerance or type 2 diabetes mellitus (61 ± 16 years, body mass index (BMI) 26 ± 3 kg/m², total cholesterol (TC) 219 ± 53 mg/dL, triglyceride (TG) 183 ± 83 mg/dL, high-density lipoprotein-cholesterol (HDL-C) 46 ± 8 mg/dL, fasting plasma glucose 133 ± 31 mg/dL and HbA1c 6.2 ± 0.8%). Subjects were given either bezafibrate or fenofibrate for 8 weeks, discontinued for 4 weeks and then switched to the other fibrate for 8 weeks. Circulating PCSK9 levels and other metabolic parameters, including adiponectin, leptin and urine 8-hydroxy-2'-deoxyguanosine (8-OHdG) were measured at 0, 8, 12 and 20 weeks.Plasma PCSK9 concentrations were significantly increased (+39.7% for bezafibrate and +66.8% for fenofibrate, p<0.001) in all patients except for one subject when treated with bezafibrate. Both bezafibrate and fenofibrate caused reductions in TG (-38.3%, p<0.001 vs. -32.9%, p<0.01) and increases in HDL-C (+18.0%, p<0.001 vs. +11.7%, p<0.001). Fenofibrate significantly reduced serum cholesterol levels (TC, -11.2%, p<0.01; non-HDL-C, -17.3%, p<0.01; apolipoprotein B, -15.1%, p<0.01), whereas bezafibrate significantly improved glucose tolerance (insulin, -17.0%, p<0.05) and metabolic markers (γ-GTP, -38.9%, p<0.01; adiponectin, +15.4%, p<0.05; urine 8-OHdG/Cre, -9.5%, p<0.05).Both bezafibrate and fenofibrate increased plasma PCSK9 concentrations. The addition of a PCSK9 inhibitor to each fibrate therapy may achieve beneficial cholesterol lowering along with desirable effects of respective fibrates." @default.
- W1963500532 created "2016-06-24" @default.
- W1963500532 creator A5001121957 @default.
- W1963500532 creator A5001844280 @default.
- W1963500532 creator A5015289084 @default.
- W1963500532 creator A5019149581 @default.
- W1963500532 creator A5025214510 @default.
- W1963500532 creator A5043154152 @default.
- W1963500532 creator A5047022170 @default.
- W1963500532 creator A5048293793 @default.
- W1963500532 creator A5053722092 @default.
- W1963500532 creator A5060616979 @default.
- W1963500532 creator A5062351415 @default.
- W1963500532 creator A5063363434 @default.
- W1963500532 creator A5080228002 @default.
- W1963500532 creator A5087125829 @default.
- W1963500532 date "2011-07-01" @default.
- W1963500532 modified "2023-10-12" @default.
- W1963500532 title "Comparison of effects of bezafibrate and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 and adipocytokine levels in dyslipidemic subjects with impaired glucose tolerance or type 2 diabetes mellitus: Results from a crossover study" @default.
- W1963500532 cites W1964279010 @default.
- W1963500532 cites W1966941449 @default.
- W1963500532 cites W1968488102 @default.
- W1963500532 cites W1975018096 @default.
- W1963500532 cites W1977666051 @default.
- W1963500532 cites W1981261500 @default.
- W1963500532 cites W1986438251 @default.
- W1963500532 cites W1994381425 @default.
- W1963500532 cites W1997994134 @default.
- W1963500532 cites W2005054339 @default.
- W1963500532 cites W2005965794 @default.
- W1963500532 cites W2013982259 @default.
- W1963500532 cites W2014259643 @default.
- W1963500532 cites W2015643123 @default.
- W1963500532 cites W2021976026 @default.
- W1963500532 cites W2023307344 @default.
- W1963500532 cites W2025861882 @default.
- W1963500532 cites W2030430722 @default.
- W1963500532 cites W2037379679 @default.
- W1963500532 cites W2049031546 @default.
- W1963500532 cites W2059995099 @default.
- W1963500532 cites W2063025601 @default.
- W1963500532 cites W2071154679 @default.
- W1963500532 cites W2076648603 @default.
- W1963500532 cites W2082881627 @default.
- W1963500532 cites W2083682427 @default.
- W1963500532 cites W2083981059 @default.
- W1963500532 cites W2090101356 @default.
- W1963500532 cites W2092101873 @default.
- W1963500532 cites W2096346573 @default.
- W1963500532 cites W2102273744 @default.
- W1963500532 cites W2103518970 @default.
- W1963500532 cites W2104012044 @default.
- W1963500532 cites W2105119801 @default.
- W1963500532 cites W2106759269 @default.
- W1963500532 cites W2111148312 @default.
- W1963500532 cites W2117011155 @default.
- W1963500532 cites W2119708151 @default.
- W1963500532 cites W2125528229 @default.
- W1963500532 cites W2126229169 @default.
- W1963500532 cites W2127729207 @default.
- W1963500532 cites W2137116210 @default.
- W1963500532 cites W2139315494 @default.
- W1963500532 cites W2139575534 @default.
- W1963500532 cites W2140241764 @default.
- W1963500532 cites W2148607472 @default.
- W1963500532 cites W2153759698 @default.
- W1963500532 cites W2154862144 @default.
- W1963500532 cites W2155574205 @default.
- W1963500532 cites W2156019168 @default.
- W1963500532 cites W2160761735 @default.
- W1963500532 cites W4299601871 @default.
- W1963500532 doi "https://doi.org/10.1016/j.atherosclerosis.2011.02.012" @default.
- W1963500532 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21411093" @default.
- W1963500532 hasPublicationYear "2011" @default.
- W1963500532 type Work @default.
- W1963500532 sameAs 1963500532 @default.
- W1963500532 citedByCount "38" @default.
- W1963500532 countsByYear W19635005322012 @default.
- W1963500532 countsByYear W19635005322013 @default.
- W1963500532 countsByYear W19635005322014 @default.
- W1963500532 countsByYear W19635005322015 @default.
- W1963500532 countsByYear W19635005322016 @default.
- W1963500532 countsByYear W19635005322017 @default.
- W1963500532 countsByYear W19635005322018 @default.
- W1963500532 countsByYear W19635005322019 @default.
- W1963500532 countsByYear W19635005322021 @default.
- W1963500532 countsByYear W19635005322023 @default.
- W1963500532 crossrefType "journal-article" @default.
- W1963500532 hasAuthorship W1963500532A5001121957 @default.
- W1963500532 hasAuthorship W1963500532A5001844280 @default.
- W1963500532 hasAuthorship W1963500532A5015289084 @default.
- W1963500532 hasAuthorship W1963500532A5019149581 @default.
- W1963500532 hasAuthorship W1963500532A5025214510 @default.
- W1963500532 hasAuthorship W1963500532A5043154152 @default.
- W1963500532 hasAuthorship W1963500532A5047022170 @default.
- W1963500532 hasAuthorship W1963500532A5048293793 @default.
- W1963500532 hasAuthorship W1963500532A5053722092 @default.
- W1963500532 hasAuthorship W1963500532A5060616979 @default.